Identification
- Summary
Gluconic Acid is an electrolyte supplement used in total parenteral nutrition.
- Brand Names
- Isolyte S, Isolyte S pH 7.4, Isoplate, Normosol-R, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasmalyte A
- Generic Name
- Gluconic Acid
- DrugBank Accession Number
- DB13180
- Background
Commonly found in salts with sodium and calcium. Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Gluconic Acid (DB13180)
- Weight
- Average: 196.1553
Monoisotopic: 196.058302738 - Chemical Formula
- C6H12O7
- Synonyms
- D-Gluconic Acid
- Dextronic acid
- Maltonic acid
- External IDs
- E-574
- INS no.574
- INS-574
- NSC-77381
- Pentahydroxycaproic acid
Pharmacology
- Indication
For use as part of electrolyte supplementation in total parenteral nutrition [FDA Label].
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Used as part of electrolyte salts to maintain cation-anion balance in solutions.
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Gluconic Acid. Alfentanil The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Alfentanil. Amiloride The risk or severity of dehydration can be increased when Amiloride is combined with Gluconic Acid. Amiodarone The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Amiodarone. Amlodipine The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Amlodipine. Bendroflumethiazide The risk or severity of dehydration can be increased when Bendroflumethiazide is combined with Gluconic Acid. Benzhydrocodone The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Benzhydrocodone. Benzthiazide The risk or severity of dehydration can be increased when Benzthiazide is combined with Gluconic Acid. Bepridil The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Bepridil. Bromotheophylline The risk or severity of dehydration can be increased when Bromotheophylline is combined with Gluconic Acid. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sodium gluconate R6Q3791S76 527-07-1 UPMFZISCCZSDND-JJKGCWMISA-M - Active Moieties
Name Kind UNII CAS InChI Key Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BİOFLEKS İZOLEKS-S pH 7.4 ÇÖZELTİSİ 1000 ML (PVC TORBA) SETLİ Sodium gluconate (0.5 g/100ml) + Dipotassium phosphate (0.012 g/100ml) + Magnesium chloride hexahydrate (0.03 g/100ml) + Monopotassium phosphate (0.00082 g/100ml) + Potassium chloride (0.037 g/100ml) + Sodium acetate trihydrate (0.37 g/100ml) + Sodium chloride (0.53 g/100ml) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey 
BİOFLEKS İZOLEKS-S pH 7.4 ÇÖZELTİSİ 500 ML (PVC TORBA) SETLİ Sodium gluconate (0.5 g/100ml) + Dipotassium phosphate (0.012 g/100ml) + Magnesium chloride hexahydrate (0.03 g/100ml) + Monopotassium phosphate (0.00082 g/100ml) + Potassium chloride (0.037 g/100ml) + Sodium acetate trihydrate (0.37 g/100ml) + Sodium chloride (0.53 g/100ml) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey BİOFLEKS İZOLEKS-S pH 7.4 ÇÖZELTİSİ 500 ML (PVC TORBA) SETSİZ Sodium gluconate (0.5 g/100ml) + Dipotassium phosphate (0.012 g/100ml) + Magnesium chloride hexahydrate (0.03 g/100ml) + Monopotassium phosphate (0.00082 g/100ml) + Potassium chloride (0.037 g/100ml) + Sodium acetate trihydrate (0.37 g/100ml) + Sodium chloride (0.53 g/100ml) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey Hyperlyte (multi-electrolyte Concentrate) Sodium gluconate (1.09 g / 25 mL) + Calcium acetate (440 mg / 25 mL) + Magnesium acetate (860 mg / 25 mL) + Potassium acetate (690 mg / 25 mL) + Potassium chloride (2.46 g / 25 mL) + Sodium acetate (2.72 g / 25 mL) Liquid Intravenous B. Braun Medical Inc. 1998-09-04 2017-07-15 Canada 
Isolyte S Sodium gluconate (0.5 g/100mL) + Magnesium chloride hexahydrate (0.03 g/100mL) + Potassium chloride (0.037 g/100mL) + Sodium acetate trihydrate (0.37 g/100mL) + Sodium chloride (0.53 g/100mL) Injection, solution Intravenous B. Braun Medical Inc. 1989-09-29 Not applicable US 
Isolyte S (multi-electrolyte Injection) Sodium gluconate (500 mg / 100 mL) + Magnesium chloride (30 mg / 100 mL) + Potassium chloride (37 mg / 100 mL) + Sodium acetate (370 mg / 100 mL) + Sodium chloride (530 mg / 100 mL) Solution Intravenous B. Braun Medical Inc. 1992-12-31 Not applicable Canada Isolyte S in Dextrose Sodium gluconate (0.5 g/100mL) + D-glucose monohydrate (5 g/100mL) + Magnesium chloride hexahydrate (0.03 g/100mL) + Potassium chloride (0.037 g/100mL) + Sodium acetate trihydrate (0.37 g/100mL) + Sodium chloride (0.53 g/100mL) Injection, solution Intravenous B. Braun Medical Inc. 1993-08-09 2014-05-30 US Isolyte S pH 7.4 Sodium gluconate (0.5 g/100mL) + Magnesium chloride hexahydrate (0.03 g/100mL) + Monopotassium phosphate (0.00082 g/100mL) + Potassium chloride (0.037 g/100mL) + Sodium acetate trihydrate (0.37 g/100mL) + Sodium chloride (0.53 g/100mL) + Sodium phosphate, dibasic, unspecified form (0.012 g/100mL) Injection, solution Intravenous B. Braun Medical Inc. 1989-09-29 Not applicable US Isolyte S Ph 7.4 (multi-electrolyte Injection) Sodium gluconate (500 mg / 100 mL) + Magnesium chloride (30 mg / 100 mL) + Monopotassium phosphate (820 mcg / 100 mL) + Potassium chloride (37 mg / 100 mL) + Sodium acetate (370 mg / 100 mL) + Sodium chloride (530 mg / 100 mL) + Sodium phosphate, dibasic (12 mg / 100 mL) Solution Intravenous B. Braun Medical Inc. 1996-09-10 Not applicable Canada Isolyte S With 5% Dextrose Inj Sodium gluconate (500 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Magnesium chloride (30 mg / 100 mL) + Potassium chloride (37 mg / 100 mL) + Sodium acetate (370 mg / 100 mL) + Sodium chloride (530 mg / 100 mL) Solution Intravenous B. Braun Medical Inc. 1996-09-10 2018-12-12 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ISOLYTE SISE 1000 ML(SETLI) Sodium gluconate (0.5 %) + Magnesium chloride (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %) + Sodium phosphate, dibasic, heptahydrate (0.012 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey ISOLYTE SISE 1000 ML(SETSIZ) Sodium gluconate (0.5 %) + Magnesium chloride (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %) + Sodium phosphate, dibasic, heptahydrate (0.012 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey ISOLYTE SISE 500 ML(SETSIZ) Sodium gluconate (0.5 %) + Magnesium chloride (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %) + Sodium phosphate, dibasic, heptahydrate (0.012 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey ISOLYTE-S PH 7.4 PVC 1000 ML(SETLI) Sodium gluconate (0.5 %) + Magnesium chloride hexahydrate (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %) + Sodium phosphate, dibasic, heptahydrate (0.012 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey ISOLYTE-S PH 7.4 PVC 1000 ML(SETSIZ) Sodium gluconate (0.5 %) + Magnesium chloride hexahydrate (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %) + Sodium phosphate, dibasic, heptahydrate (0.012 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey ISOLYTE-S PH 7.4 PVC 500 ML(SETLI) Sodium gluconate (0.5 %) + Magnesium chloride hexahydrate (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %) + Sodium phosphate, dibasic, heptahydrate (0.012 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey ISOLYTE-S PH 7.4 PVC 500 ML(SETSIZ) Sodium gluconate (0.5 %) + Magnesium chloride hexahydrate (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %) + Sodium phosphate, dibasic, heptahydrate (0.012 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey Nutrilyte Sodium gluconate (55 mg/1mL) + Calcium acetate (22 mg/1mL) + Magnesium acetate (43 mg/1mL) + Potassium acetate (34.5 mg/1mL) + Potassium chloride (125 mg/1mL) + Sodium acetate trihydrate (135 mg/1mL) Injection, solution, concentrate Intravenous American Regent 1990-09-30 2013-05-08 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Sugar acids and derivatives
- Alternative Parents
- Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Hydroxy fatty acids / Beta hydroxy acids and derivatives / Monosaccharides / Alpha hydroxy acids and derivatives / Secondary alcohols / Polyols / Monocarboxylic acids and derivatives / Carboxylic acids show 4 more
- Substituents
- Alcohol / Aliphatic acyclic compound / Alpha-hydroxy acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Fatty acid / Fatty acyl / Gluconic_acid show 11 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- gluconic acid (CHEBI:33198) / Uronic acids (C00257)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R4R8J0Q44B
- CAS number
- 526-95-4
- InChI Key
- RGHNJXZEOKUKBD-SQOUGZDYSA-N
- InChI
- InChI=1S/C6H12O7/c7-1-2(8)3(9)4(10)5(11)6(12)13/h2-5,7-11H,1H2,(H,12,13)/t2-,3-,4+,5-/m1/s1
- IUPAC Name
- (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid
- SMILES
- OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000625
- KEGG Compound
- C00257
- PubChem Compound
- 10690
- PubChem Substance
- 347829282
- ChemSpider
- 10240
- ChEBI
- 33198
- ChEMBL
- CHEMBL464345
- ZINC
- ZINC000001531008
- PharmGKB
- PA449770
- PDBe Ligand
- GCO
- Wikipedia
- Gluconic_acid
- PDB Entries
- 1bgg / 1xlf / 3o03 / 3oy8 / 3qke / 3t6c / 3twb / 4k2s / 4zlg / 6e9n … show 1 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Hypovolaemia 1 4 Terminated Treatment Dehydration / Gastroenteritis 1 4 Unknown Status Basic Science Nephrotoxicity 1 3 Completed Prevention Acute Kidney Injury (AKI) / Critically Ill Patients 1 3 Completed Treatment Anesthesia therapy 1 3 Completed Treatment Delayed Graft Function / End Stage Renal Disease (ESRD) / Transplanted Kidney Complication 1 3 Recruiting Treatment Anesthesia Intubation Complications / Hypotension and Shock / Induction of Intraoperative Hypotension / Intubation; Complication / Respiratory Failure 1 3 Recruiting Treatment Sepsis / Shock 1 2 Active Not Recruiting Treatment Myocardial Infarction, Anterior Wall 1 2 Completed Prevention Acute Kidney Injury (AKI) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous Liquid Intravenous Injection, solution, concentrate Intravenous Irrigant Irrigation Injection, solution Intravenous Injection Intravenous 30 mg/100ml Solution Parenteral Powder, for solution Irrigation; Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 159.0 mg/mL ALOGPS logP -2.6 ALOGPS logP -3.4 Chemaxon logS -0.09 ALOGPS pKa (Strongest Acidic) 3.39 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 138.45 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 38.27 m3·mol-1 Chemaxon Polarizability 17.15 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created at June 09, 2017 02:30 / Updated at June 12, 2020 16:53